Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
McKesson
Fuji
McKinsey
Julphar
Johnson and Johnson
Harvard Business School
Mallinckrodt

Generated: September 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,514,953

« Back to Dashboard

Which drugs does patent 6,514,953 protect, and when does it expire?

Patent 6,514,953 protects LEXIVA and is included in one NDA.

Protection for LEXIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-seven patent family members in forty-six countries.

Summary for Patent: 6,514,953
Title: Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2-(phosphonooxy)propylcarbamate
Abstract:The invention relates to calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2-(phosphonooxy)propylcarbamate, to processes for its preparation, and to its use in the treatment of diseases caused by retroviruses. ##STR1##
Inventor(s): Armitage; Ian Gordon (Arlesey, GB), Searle; Andrew David (Stevenage, GB), Singh; Hardev (Dartford, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/744,051
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Dosage form; Process; Formulation;

Drugs Protected by US Patent 6,514,953

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,514,953

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9815567Jul 18, 1998
PCT Information
PCT FiledJuly 15, 1999PCT Application Number:PCT/EP99/04991
PCT Publication Date:January 27, 2000PCT Publication Number: WO00/04033

International Family Members for US Patent 6,514,953

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 019388 ➤ Try a Free Trial
Austria 229964 ➤ Try a Free Trial
Australia 5037999 ➤ Try a Free Trial
Australia 766056 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Chubb
Fuji
McKesson
Deloitte
Farmers Insurance
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.